Cellphire Therapeutics is committed to transforming hemostasis management with innovative products that fill critical gaps in the treatment of bleeding patients. Our lead clinical-stage candidate, Thrombosomes®, is an activated platelet-based hemostatic agent. The product is currently in a Phase 2 clinical trial in bleeding thrombocytopenic patients. Thrombosomes® has also been given orphan drug designation for the treatment of Acute Radiation Sickness by the U.S. Food and Drug Administration.

Cellphire is identifying and developing other novel cellular-based therapies to address unmet needs in anti-thrombotic reversal and regenerative medicine, among others.

To learn more about the thinking behind our science, click here.

Building a Pipeline of Cellular Therapies

Prior Phase 1 safety studies support all Freeze-dried platelet-derived hemostat (FPH) technology products.

Want to hear more about our trials and research?

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.